Remote Patient Monitoring

Illustrative case Fictional example

This fictional case is not clinical, legal, procurement, information-governance, or regulatory advice. It describes no real hospital, service, product, completed work, or claim of clinical efficacy.

Domain
Regulated healthcare service
Delivery approach
Controlled pilot with clinical governance
Scenario
Test whether vendor-supported remote monitoring can improve post-discharge follow-up without unacceptable safety, equity, privacy, or workload effects.
Decision sought
Approve a 150-participant vendor-service pilot and evaluation, with no commitment to scale.
Investment scale
Up to USD 420,000 for pilot and evaluation
Planning horizon
Six months' enrollment plus final follow-up and evaluation
Primary constraints
Patient safety, consent, evidence quality, equitable access, information governance, and clinical capacity.
Evidence basis
Fictional service baseline and uncertain modeled value to be tested through a governed pilot.
Demonstrates
Reversible evidence-buying, regulated pilot governance, ethical option appraisal, and separation of modeled value from cash savings.

Document Control

Field Decision record
Organization Northstar Regional Hospital (fictional)
Version / date 1.0 / 24 August 2026
Document status Draft for committee decision
Decision Approve, reject, or return a staged pilot for revision
Clinical sponsor Chief Medical Officer
Accountable business owner Chief Operating Officer
Proposed authority Executive Investment and Clinical Governance Committee
Funding requested now Up to USD 420,000 for pilot and evaluation; no scale commitment

Executive Summary

Northstar considers remote patient monitoring (RPM) for adults discharged home after a heart-failure admission. Follow-up is fragmented across calls, appointments, and patient contact. RPM would not replace urgent-care instructions, professional judgment, or existing pathways. The pilot tests whether a vendor service can add structured observation and escalation without unacceptable safety, privacy, equity, or workload consequences.

Three options were considered: current follow-up, a vendor service, and custom build. The recommendation is a 150-participant, 90-day-per-participant pilot, with six months' enrollment and three months' final follow-up and evaluation. Approval is requested for USD 420,000, subject to assurance gates. Scale requires a separate decision.

The pilot buys evidence, not promised savings. Possible scale costs USD 900,000 yearly for 600 participants. Modeled avoided utilization has an uncertain USD 180,000 annual accounting value and is not cash-releasing. Value rests on reversible learning and potential quality, access, and capacity value—not pricing human outcomes or assuming clinical benefit.

Strategic/Clinical Case and Current State

The cohort is adults discharged home after a heart-failure admission who meet a locally approved protocol, can consent through an approved process, and are considered suitable by the responsible team. Participation is optional and usual follow-up remains available. Accountable clinicians will approve eligibility and escalation rules.

Illustrative data indicate 600 eligible discharges annually. Calls are inconsistently timed and documentation crosses workflows. A baseline review suggests 22% have an unplanned emergency visit or readmission within 30 days; this requires validation and does not establish preventability. The need is a consistent, measurable transition model, not predetermined technology.

Objectives and Success Measures

Objective Pilot measure and threshold Owner
Safe operation Assess 100% of serious events; no unresolved safety finding at close Safety Officer
Reliable service Activate 90% within 48 hours; review 95% of priority escalations within approved windows Transitional Care
Acceptability At least 60% of enrolled participants respond; 75% of responding participants and 70% of responding affected staff rate service acceptable Experience / Nursing
Alarm burden At most two escalations per participant-week and 20% non-actionable after tuning Nursing
Equity Report access and completion by agreed groups; investigate unexplained gaps over 10 points Equity Lead
Decision evidence Estimate utilization, workload, quality, and cost with uncertainty; make no underpowered efficacy claim Evaluation Lead

Constraints, Ethics, Equity, and Dependencies

The pilot must follow approved pathways, applicable law, payer and workforce rules, procurement policy, and the product's lawfully supported intended use. The hospital will verify authorizations and evidence; this case asserts none. Participants must understand monitoring responsibility, hours, limitations, withdrawal, and urgent-help instructions.

Before enrollment, the appropriate institutional function must document whether the activity is service improvement, human-subject research, or requires ethics or research-board review. Any review, approval, consent, registration, or other safeguards identified by that determination must be completed before enrollment. This business case does not presume a classification or jurisdiction-specific outcome.

Smartphone ownership, language, disability, digital confidence, or ability to pay cannot be hidden criteria. Provide loan equipment, connectivity, interpreters, accessible materials, authorized caregiver support, and a non-digital alternative. Dependencies include clinical coverage, record integration, access controls, logistics, training, baseline data, and evaluation design.

Options

  1. Current follow-up: retain calls, appointments, and patient contact; improve scripts and audit. Lowest incremental cost, but limited visibility and evaluability.
  2. Regulated vendor service: procure a service whose products are verified for the proposed use, including devices, connectivity, support, dashboards, audit trails, and integration. Faster and reversible, but creates supplier and recurring-cost dependencies.
  3. Custom build: develop software, interfaces, operations, and controls. Greater control, but an estimated 24–30 months, USD 4.8 million build, USD 1.4 million annual operation, and greater validation, cyber, maintenance, and regulatory responsibility.

Options Appraisal

Scores use 1 (poor) to 5 (strong). Weights and scores are judgments to be validated at approval.

Criterion Weight Current Vendor Custom
Safety and governance feasibility 30% 3 4 2
Time to decision evidence 20% 2 5 1
Equity and participant support 15% 2 4 3
Affordability 15% 5 3 1
Workflow and technical feasibility 10% 4 4 2
Reversibility / flexibility 10% 5 4 2
Weighted score 100% 3.25 4.05 1.80

Current follow-up remains the fallback. Custom build is disproportionate before safety, adoption, and workflow are demonstrated. The vendor option is the strongest staged route, conditional on due diligence.

Recommended Option and Pilot/Scale Scope

Approve procurement and a pilot of 150 participants in one transitional-care team, each for up to 90 days. Scope includes consent, equipment, connectivity, onboarding, contracted observations, protocol routing, documentation, support, training, evaluation, and safe exit. Excluded are autonomous diagnosis or treatment, replacement of emergency pathways, other cohorts, and post-pilot procurement.

Possible scale is 600 participants annually for three years in the same cohort. This planning scenario requires successful gates, refreshed evidence, workforce capacity, and separate approval.

Financial Case

Pilot cost is vendor setup/service (USD 190,000), integration/security (USD 80,000), 0.8 FTE clinical backfill (USD 85,000), evaluation/equity support (USD 40,000), and rounded 6% contingency (USD 25,000): USD 420,000. Any forecast above the USD 420,000 pilot authorization cap requires committee reapproval before further commitment or expenditure beyond the cap.

For 600 annual episodes, vendor service at USD 900 each (USD 540,000), staffing (USD 260,000), and governance, support, evaluation, and security (USD 100,000) total USD 900,000 yearly. Year 1 adds USD 120,000 transition cost. Nominal pilot-plus-scale cost is USD 420,000 + USD 1.02 million + USD 900,000 + USD 900,000 = USD 3.24 million.

At a 4% annual discount rate, present-value cost is USD 3.03 million: USD 420,000 now, then USD 981,000, USD 832,000, and USD 800,000. Applying an exploratory 15% relative change to the unvalidated 22% baseline gives about 20 modeled avoided events yearly. At USD 9,000 accounting cost each, modeled gross avoided utilization is about USD 180,000 yearly, or USD 500,000 present value over three years. This is uncertain capacity value, not an assured clinical effect or budget reduction. No cash-releasing savings are claimed and staffing is unchanged.

Quantified financial NPV is therefore negative USD 2.53 million. Value-for-money rests on a capped pilot resolving safety, operational, equity, and adoption uncertainty before scale. Recurring cost is USD 1,500 per participant; nominal cost is about USD 1,660 across 1,950 pilot-and-scale episodes.

Sensitivity: a 20% vendor-price rise adds USD 324,000 over three years. At 400 annual participants with fixed staffing, cost is USD 720,000, or USD 1,800 each. A 0–25% relative utilization change gives USD 0–USD 297,000 annual accounting value. None is cash-releasing without an approved budget action.

Commercial, Information Governance, and Delivery Approach

Procurement will assess intended use, evidence, service levels, subcontractors, accessibility, interoperability, cyber controls, continuity, standing, price, exit, data deletion/return, audit, and liability. Award requires legal, procurement, safety, privacy, and security approval. The hospital retains clinical accountability.

Before live data, complete a data-protection assessment, data map, records schedule, role/access model, incident process, and subprocessor review. Minimize collection; prohibit secondary use, model training, or marketing unless separately lawful and approved. Delivery uses sandbox testing, simulation, phased enrollment, early-life review, and documented fallback.

Pilot Gates and Timeline

Timing Gate Evidence required
Months 0–2 Contract readiness Due diligence, affordability, exit, no critical finding
Months 2–3 Launch authorization Pathway, safety case, assurance, training, simulation, downtime plan
Months 3–5 Controlled start Review first 20 participants before increasing enrollment
At 60 participants Continue / adapt / pause Safety, response times, burden, equity, consent quality, and data completeness
Months 3–8 Complete enrollment Up to 150 participants, within approved capacity
Month 11 Close / scale decision Final follow-up, independent evaluation, refreshed case

Risks, Disbenefits, and Responses

Risk or disbenefit Response
Patient harm from missed/delayed escalation Approved protocol, simulation, response monitoring, fallback, safety review
Privacy breach or excessive surveillance Minimize data; least privilege, audit, retention, incident controls
Inequitable access or completion Loan kit/connectivity, accessibility, interpreters, non-digital route, stratified monitoring
Alarm burden and staff fatigue Enrollment caps, staffed roster, controlled tuning, alert review
Fragmented workflow / duplicate records Integration tests, one accountable queue, reconciliation audits
Consent implies continuous emergency monitoring Plain language, teach-back, hours, withdrawal, usual-care alternative
Vendor failure, lock-in, or outage Service levels, continuity tests, portability, exit support, manual fallback
Anxiety or participant/caregiver burden Optional participation, proportionate schedule, support, easy withdrawal

Benefits Realization

The COO owns value; Transitional Care owns activation and workload; the Safety Officer owns safety evidence; the Equity Lead owns access analysis; Finance validates costs. Freeze baselines before launch. Review weekly during controlled start, monthly thereafter, at close, and quarterly for two years if scaled. Report denominators, missing data, uncertainty, and unintended effects; reconcile vendor reports to hospital sources.

Governance and Safety/Review Triggers

A multidisciplinary clinical safety group reports to the approving committee. A serious event is death, unplanned intensive-care admission, permanent harm, or another event designated serious by the Safety Officer that may be associated with the service, including missed or delayed escalation. Classification does not assume causation.

Every serious event receives a documented assessment within two business days, or sooner if required, covering:

  • facts and relatedness;
  • preventability;
  • protocol performance; and
  • required action.

Urgent review within 24 hours is required for any of these triggers:

  • one probably service-related death or permanent harm;
  • two probably service-related serious events within 30 days;
  • more than 5% of priority escalations outside approved windows over seven days;
  • a material privacy or security incident; or
  • unsafe staffing.

The Safety Officer may pause affected activity while the group decides whether to continue, adapt, narrow, pause, or terminate. These are governance thresholds, not automated clinical stopping rules; any credible hazard may prompt immediate protective action.

Reopen the case when any of these conditions applies:

  • the current pilot forecast exceeds the USD 420,000 authorization cap, which requires committee reapproval;
  • launch slips by more than eight weeks;
  • equity mitigations fail;
  • lawful vendor support changes; or
  • the scale value proposition changes materially.

Decision Required and Approval Conditions

Approve up to USD 420,000 for the staged pilot. This does not authorize scale, establish efficacy, reduce staffing, or commit to a supplier.

Approval is conditional on all of the following:

  • validated baseline and eligibility protocol;
  • completed procurement;
  • documented institutional determination of the activity's service-improvement, human-subject-research, or ethics/research-board review status, with all resulting requirements completed;
  • approved safety case and consent process;
  • approved data-protection assessment and security test;
  • approved accessibility and workforce plans;
  • approved evaluation protocol;
  • approved downtime and exit plan;
  • completed liability review;
  • named owners and patient representation; and
  • launch authorization by the Clinical Sponsor and Safety Officer.

Any unmet condition returns the proposal to the committee.